KPTI - Karyopharm Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue1,605154250
Cost of Revenue---
Gross Profit1,605154250
Operating Expenses
Research Development107,27386,93897,744
Selling General and Administrative24,87023,94821,582
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss-130,538-110,732-119,076
Income from Continuing Operations
Total Other Income/Expenses Net1,6171,294895
Earnings Before Interest and Taxes-128,921-109,438-118,181
Interest Expense---
Income Before Tax-128,921-109,438-118,181
Income Tax Expense63139-
Minority Interest---
Net Income From Continuing Ops-128,984-109,577-118,181
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-128,984-109,577-118,181
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-128,984-109,577-118,181